Multicenter evaluation of the XT modular coronary stent: Clinical and angiographic results

Pasquale Spadaro, Roberto Violini, Antonio Marzocchi, David Antoniucci, Federico Piscione, Cinzia Marrozzini, Renato Valenti, Angelo Cioppa, Antonio Colombo, Carlo Di Mario

Research output: Contribution to journalArticle

Abstract

BACKGROUND. In the past few years, the indications for stent implantation have broadened, along with a larger number of available designs. The Bard XT stent is a new modular stent with an original structure and design. METHODS. To evaluate the new Bard XT stent, we studied its use in a multicenter experience in 163 patients, with a total of 168 lesions and 180 implanted units. RESULTS. Despite the predominance of complex lesions, the procedural success rate was 98%, with only a 2% failure of stent implantation. There was only one death (no-fellow phenomenon in a rescue primary PTCA in a patient in cardiogenic shock) without other major periprocedural complications. Centralized QCA showed a statistically significant increase of MLD (from 0.73 ± 0.43 mm to 2.71 ± 0.40 mm, p <0.0001) and DS reduction (from 73.8 ± 15.1% pre-treatment to 7.8 ± 0.4% after stent implantation; p <0.0001). Aspirin and ticlopidine were routinely administered after the procedure. Thirty-day follow-up reported only one case of subacute stent thrombosis (in the first day), treated with re-PTCA. CONCLUSIONS. In a group of patients with complex lesions, we obtained a high rate of success with a low incidence of complications. The Bard XT stent had a high-performance profile with normalization of vessel diameter and angiographic results similar to the ones obtained with the 'slotted tube' stents.

Original languageEnglish
Pages (from-to)241-245
Number of pages5
JournalGiornale Italiano di Cardiologia
Volume29
Issue number3
Publication statusPublished - Mar 1999

Fingerprint

Stents
Ticlopidine
Cardiogenic Shock
Aspirin
Thrombosis
Incidence

Keywords

  • Coronary heart disease
  • PTCA
  • Stent

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Spadaro, P., Violini, R., Marzocchi, A., Antoniucci, D., Piscione, F., Marrozzini, C., ... Di Mario, C. (1999). Multicenter evaluation of the XT modular coronary stent: Clinical and angiographic results. Giornale Italiano di Cardiologia, 29(3), 241-245.

Multicenter evaluation of the XT modular coronary stent : Clinical and angiographic results. / Spadaro, Pasquale; Violini, Roberto; Marzocchi, Antonio; Antoniucci, David; Piscione, Federico; Marrozzini, Cinzia; Valenti, Renato; Cioppa, Angelo; Colombo, Antonio; Di Mario, Carlo.

In: Giornale Italiano di Cardiologia, Vol. 29, No. 3, 03.1999, p. 241-245.

Research output: Contribution to journalArticle

Spadaro, P, Violini, R, Marzocchi, A, Antoniucci, D, Piscione, F, Marrozzini, C, Valenti, R, Cioppa, A, Colombo, A & Di Mario, C 1999, 'Multicenter evaluation of the XT modular coronary stent: Clinical and angiographic results', Giornale Italiano di Cardiologia, vol. 29, no. 3, pp. 241-245.
Spadaro P, Violini R, Marzocchi A, Antoniucci D, Piscione F, Marrozzini C et al. Multicenter evaluation of the XT modular coronary stent: Clinical and angiographic results. Giornale Italiano di Cardiologia. 1999 Mar;29(3):241-245.
Spadaro, Pasquale ; Violini, Roberto ; Marzocchi, Antonio ; Antoniucci, David ; Piscione, Federico ; Marrozzini, Cinzia ; Valenti, Renato ; Cioppa, Angelo ; Colombo, Antonio ; Di Mario, Carlo. / Multicenter evaluation of the XT modular coronary stent : Clinical and angiographic results. In: Giornale Italiano di Cardiologia. 1999 ; Vol. 29, No. 3. pp. 241-245.
@article{7ae4f33aa8b448cfbf76071fa1a10bc0,
title = "Multicenter evaluation of the XT modular coronary stent: Clinical and angiographic results",
abstract = "BACKGROUND. In the past few years, the indications for stent implantation have broadened, along with a larger number of available designs. The Bard XT stent is a new modular stent with an original structure and design. METHODS. To evaluate the new Bard XT stent, we studied its use in a multicenter experience in 163 patients, with a total of 168 lesions and 180 implanted units. RESULTS. Despite the predominance of complex lesions, the procedural success rate was 98{\%}, with only a 2{\%} failure of stent implantation. There was only one death (no-fellow phenomenon in a rescue primary PTCA in a patient in cardiogenic shock) without other major periprocedural complications. Centralized QCA showed a statistically significant increase of MLD (from 0.73 ± 0.43 mm to 2.71 ± 0.40 mm, p <0.0001) and DS reduction (from 73.8 ± 15.1{\%} pre-treatment to 7.8 ± 0.4{\%} after stent implantation; p <0.0001). Aspirin and ticlopidine were routinely administered after the procedure. Thirty-day follow-up reported only one case of subacute stent thrombosis (in the first day), treated with re-PTCA. CONCLUSIONS. In a group of patients with complex lesions, we obtained a high rate of success with a low incidence of complications. The Bard XT stent had a high-performance profile with normalization of vessel diameter and angiographic results similar to the ones obtained with the 'slotted tube' stents.",
keywords = "Coronary heart disease, PTCA, Stent",
author = "Pasquale Spadaro and Roberto Violini and Antonio Marzocchi and David Antoniucci and Federico Piscione and Cinzia Marrozzini and Renato Valenti and Angelo Cioppa and Antonio Colombo and {Di Mario}, Carlo",
year = "1999",
month = "3",
language = "English",
volume = "29",
pages = "241--245",
journal = "Giornale Italiano di Cardiologia",
issn = "0046-5968",
publisher = "Societa Italiana di Cardiologia",
number = "3",

}

TY - JOUR

T1 - Multicenter evaluation of the XT modular coronary stent

T2 - Clinical and angiographic results

AU - Spadaro, Pasquale

AU - Violini, Roberto

AU - Marzocchi, Antonio

AU - Antoniucci, David

AU - Piscione, Federico

AU - Marrozzini, Cinzia

AU - Valenti, Renato

AU - Cioppa, Angelo

AU - Colombo, Antonio

AU - Di Mario, Carlo

PY - 1999/3

Y1 - 1999/3

N2 - BACKGROUND. In the past few years, the indications for stent implantation have broadened, along with a larger number of available designs. The Bard XT stent is a new modular stent with an original structure and design. METHODS. To evaluate the new Bard XT stent, we studied its use in a multicenter experience in 163 patients, with a total of 168 lesions and 180 implanted units. RESULTS. Despite the predominance of complex lesions, the procedural success rate was 98%, with only a 2% failure of stent implantation. There was only one death (no-fellow phenomenon in a rescue primary PTCA in a patient in cardiogenic shock) without other major periprocedural complications. Centralized QCA showed a statistically significant increase of MLD (from 0.73 ± 0.43 mm to 2.71 ± 0.40 mm, p <0.0001) and DS reduction (from 73.8 ± 15.1% pre-treatment to 7.8 ± 0.4% after stent implantation; p <0.0001). Aspirin and ticlopidine were routinely administered after the procedure. Thirty-day follow-up reported only one case of subacute stent thrombosis (in the first day), treated with re-PTCA. CONCLUSIONS. In a group of patients with complex lesions, we obtained a high rate of success with a low incidence of complications. The Bard XT stent had a high-performance profile with normalization of vessel diameter and angiographic results similar to the ones obtained with the 'slotted tube' stents.

AB - BACKGROUND. In the past few years, the indications for stent implantation have broadened, along with a larger number of available designs. The Bard XT stent is a new modular stent with an original structure and design. METHODS. To evaluate the new Bard XT stent, we studied its use in a multicenter experience in 163 patients, with a total of 168 lesions and 180 implanted units. RESULTS. Despite the predominance of complex lesions, the procedural success rate was 98%, with only a 2% failure of stent implantation. There was only one death (no-fellow phenomenon in a rescue primary PTCA in a patient in cardiogenic shock) without other major periprocedural complications. Centralized QCA showed a statistically significant increase of MLD (from 0.73 ± 0.43 mm to 2.71 ± 0.40 mm, p <0.0001) and DS reduction (from 73.8 ± 15.1% pre-treatment to 7.8 ± 0.4% after stent implantation; p <0.0001). Aspirin and ticlopidine were routinely administered after the procedure. Thirty-day follow-up reported only one case of subacute stent thrombosis (in the first day), treated with re-PTCA. CONCLUSIONS. In a group of patients with complex lesions, we obtained a high rate of success with a low incidence of complications. The Bard XT stent had a high-performance profile with normalization of vessel diameter and angiographic results similar to the ones obtained with the 'slotted tube' stents.

KW - Coronary heart disease

KW - PTCA

KW - Stent

UR - http://www.scopus.com/inward/record.url?scp=0032944197&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032944197&partnerID=8YFLogxK

M3 - Article

C2 - 10231668

AN - SCOPUS:0032944197

VL - 29

SP - 241

EP - 245

JO - Giornale Italiano di Cardiologia

JF - Giornale Italiano di Cardiologia

SN - 0046-5968

IS - 3

ER -